Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:4236
Name carcinosarcoma
Definition A mixed cell type cancer that has_material_basis_in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.
Source DiseaseOntology.org
Alt Ids DOID:2610 DOID:1971 DOID:4234
Path disease disease of cellular proliferation cancer cell type cancer mixed cell type cancer carcinosarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03206177 Phase I Carboplatin + Galunisertib + Paclitaxel Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary Completed USA 0
NCT04041128 Phase I Olaparib PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer Completed USA 0
NCT04065269 Phase II Ceralasertib + Olaparib Ceralasertib ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) Recruiting GBR | CAN 0
NCT04149275 Phase II Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib Plus Nivolumab and Ipilimumab Women With Recurrent Gynecologic Carcinosarcoma Withdrawn USA 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0